ArticleBritish journal of cancer2003
Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.
Article in British journal of cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Clinical outcomes of tebentafusp in metastatic uveal melanoma: a systematic review and single-arm meta-analysis.Frontiers in medicine · 2026Pooled it
- Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis.Scientific reports · 2024Pooled it
- Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.British journal of cancer · 2017Trial
- IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression.Molecular cancer therapeutics · 2023Article
- Targeting Oncogenic GαCancers · 2021Review
- A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Usefulness of nivolumab plus ipilimumab immunotherapy for metastatic uveal melanoma.Proceedings (Baylor University. Medical Center) · 2020Article
- Development and optimization of orthotopic liver metastasis xenograft mouse models in uveal melanoma.Journal of translational medicine · 2020Article
- Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas.Pathology oncology research : POR · 2019Article
- Effects of Oncogenic GαMolecular cancer research : MCR · 2019Article
- Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience.Case reports in oncological medicine · 2019Article
- BRAF mutation testing in melanoma: results from a German observational multicenter study.Virchows Archiv : an international journal of pathology · 2019Observational
- Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.Ocular oncology and pathology · 2017Review
- BRAF V600E-dependent role of autophagy in uveal melanoma.Journal of cancer research and clinical oncology · 2017Article
- Mutation Profile of B-Raf Gene Analyzed by fully Automated System and Clinical Features in Japanese Melanoma Patients.Pathology oncology research : POR · 2017Article
- Article
- Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2015Article
- Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.Molecular oncology · 2014Article
- Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- Frequency of BRAF Mutation and Clinical Relevance for Primary Melanomas.Korean journal of pathology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent discovery of activating mutations in the BRAF gene in many cutaneous melanomas led us to screen the genomic sequence of BRAF exons 11 and 15 in a series of 48 intraocular (uveal) melanomas, together with control samples from three cutaneous melanomas and the SK-Mel-28 cell line, which has a BRAF mutation. The same mutation was detected in two-thirds of our cutaneous melanoma samples, but was not present in any uveal melanomas. This finding further underlines the distinction between uveal and cutaneous melanomas, and suggests that BRAF inhibitors are unlikely to benefit patients with uveal melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.